TAIPEI/TOKYO — A Taiwanese biopharmaceutical startup aspires to become a global player via the same tactics that compatriot Taiwan Semiconductor Manufacturing Co. employed to find success in the chip sector, extending Taiwan’s so-called silicon shield into new domains.
Founded in 2023, Taiwan Bio-Manufacturing Corp. is a contract manufacturer of cutting-edge treatments that use messenger RNA, gene therapy, cell therapy and biologics. Many of its roughly 100 staffers previously worked for government-backed research institutes.
